Connect your AI

CRISPR Therapeutics CRSP Restricted Cash

Restricted Cash at other companies

Cogent Biosciences, Inc.COGT

$416K—

IncyteINCY

$1.84M+10.3%

Protagonist TherapeuticsPTGX

$288K+28.0%

BridgeBio PharmaBBIO

——

RevvityRVTY

——

Regeneron PharmaceuticalsREGN

——

Other financials

Income statement

Revenue$1.5M+68.6%

Operating income-$130.2M+12.2%

Net income-$122.9M+9.6%

EPS (diluted)-$1.28+19.0%

Balance sheet

Cash & equivalents$423.3M+80.0%

Total debt$787.6M+259%

Total equity$1.8B-0.8%

Total assets$2.7B+25.8%

Cash flow

Operating cash flow-$108.9M-102%

CapEx$504.0K+145%

Free cash flow-$109.4M-102%

Valuation

Market cap$5.33B+56.4%

Enterprise value$5.69B+69.8%

P/S1,298.3×+1,208×

Profitability

Operating margin-15,754.2%-17,253pp

Net margin-13,856.5%-15,058pp

FCF margin-9,777.6%-10,759pp

Returns & leverage

Return on equity-31.2%+43.7pp

Debt / equity0.4×+0.3×

Current ratio18×+2.3×

Where this comes from

Reported directly by CRISPR Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.

The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about CRISPR Therapeutics's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is CRISPR Therapeutics's restricted cash?: CRISPR Therapeutics (CRSP) reported restricted cash of $7.63M in Q1 2026.
How has CRISPR Therapeutics's restricted cash changed year-over-year?: CRISPR Therapeutics's restricted cash decreased by 4.7% year-over-year, from $8.01M to $7.63M.
What is the long-term trend for CRISPR Therapeutics's restricted cash?: Over 5 years (2020 to 2025), CRISPR Therapeutics's restricted cash has grown at a -14.7% compound annual growth rate (CAGR), from $16.85M to $7.63M.
What does restricted cash mean?: Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.